Table 2 Univariate and multivariate analyses of factors associated with survival and cancer-free survival
From: IRF-2 inhibits cancer proliferation by promoting AMER-1 transcription in human gastric cancer
OS | DFS | |||
|---|---|---|---|---|
Hazard ratio (95%CI) | P value | Hazard ratio (95%CI) | P value | |
Univariate analyses | ||||
Sex (male vs female) | 0.875 (0.417, 1.836) | 0.725 | 1.016 (0.484, 2.131) | 0.967 |
Age, y (< 60 vs. ≥ 60) | 1.088 (0.800, 1.480) | 0.589 | 1.050 (0.772, 1.427) | 0.756 |
Histological grade (G1-2 vs. G3) | 1.871 (0.980, 3.573) | 0.058 | 1.883 (0.985,3.600) | 0.055 |
Invasive depth (mucosa to muscularis propria vs. adventitia to adjacent structure) | 0.434 (0.259, 0.728) | 0.002 | 0.405 (0.241, 0.680) | 0.001 |
Lymph nodes metastasis (≤ 2 regions vs. > 2 regions) | 0.432 (0.296, 0.629) | < 0.001 | 0.422 (0.289, 0.616) | < 0.001 |
Distant metastasis (yes vs. no) | 2.183 (0.912, 5.227) | 0.080 | 2.514 (1.050, 6.018) | 0.039 |
Position (antrum vs. others) | 0.965 (0.707, 1.318) | 0.824 | 0.945 (0.693, 1.290) | 0.723 |
TNM stage (I, II vs III, IV) | 3.775 (1.735, 8.210) | 0.001 | 3.947 (1.810, 8.607) | 0.001 |
Size (< 4 cm vs. ≥ 4 cm) | 2.571 (1.256, 5.264) | 0.010 | 2.505 (1.223, 5.131) | 0.012 |
IRF-2 (positive vs. negative) | 2.913 (1.538, 5.518) | 0.001 | 2.517 (1.337, 4.738) | 0.004 |
Multivariate analyses | ||||
IRF-2 (positive vs. negative) | 3.335 (1.736, 6.404) | < 0.001 | 2.756 (1.451, 5.234) | 0.002 |
Size (< 4 cm vs. ≥ 4 cm) | 1.628 (0.760, 3.485) | 0.209 | 1.544 (0.713, 3.347) | 0.271 |
TNM stage (I, II vs. III, IV) | 3.495 (1.516, 8.058) | 0.003 | 3.522 (1.509, 8.220) | 0.004 |